[
    [
        {
            "time": "",
            "original_text": "又一基金名将认错与反思：迎来历史上业绩最差季度，朱少醒、梁浩、袁芳、陈皓、归凯等各自亮出最新持仓",
            "features": {
                "keywords": [
                    "基金",
                    "业绩",
                    "最差季度",
                    "朱少醒",
                    "梁浩",
                    "袁芳",
                    "陈皓",
                    "归凯"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "又一基金名将认错与反思：迎来历史上业绩最差季度，朱少醒、梁浩、袁芳、陈皓、归凯等各自亮出最新持仓",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "此外，在政策、人才回流等多重因素推动下，我国创新药研发火热，这也进一步促进了我国CXO行业发展。",
            "features": {
                "keywords": [
                    "政策",
                    "人才回流",
                    "创新药",
                    "研发",
                    "CXO行业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "此外，在政策、人才回流等多重因素推动下，我国创新药研发火热，这也进一步促进了我国CXO行业发展。",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "黄金赛道CXO|从实验室化学到CXO“全家桶”，康龙化成要向药明康德看齐？",
            "features": {
                "keywords": [
                    "CXO",
                    "康龙化成",
                    "药明康德"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "黄金赛道CXO|从实验室化学到CXO“全家桶”，康龙化成要向药明康德看齐？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "速读社丨GSK公布4亿英镑英国研发设施扩建计划 罗氏/再生元新冠中和抗体疗法在日本获批上市",
            "features": {
                "keywords": [
                    "GSK",
                    "研发设施",
                    "扩建",
                    "罗氏",
                    "再生元",
                    "新冠",
                    "中和抗体",
                    "日本"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "速读社丨GSK公布4亿英镑英国研发设施扩建计划 罗氏/再生元新冠中和抗体疗法在日本获批上市",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：中报预告持续发布 关注业绩高增长个股",
            "features": {
                "keywords": [
                    "医药行业",
                    "中报预告",
                    "业绩高增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：中报预告持续发布 关注业绩高增长个股",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【券商聚焦】招商香港升药明康德(02359)目标价至250港元 重申“买入”评级",
            "features": {
                "keywords": [
                    "券商",
                    "招商香港",
                    "药明康德",
                    "目标价",
                    "买入评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【券商聚焦】招商香港升药明康德(02359)目标价至250港元 重申“买入”评级",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周观点：中报业绩陆续披露 关注基本面变动",
            "features": {
                "keywords": [
                    "医药生物",
                    "中报业绩",
                    "基本面变动"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周观点：中报业绩陆续披露 关注基本面变动",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "傅鹏博、赵枫、冯明远等顶流基金经理最新重仓股曝光",
            "features": {
                "keywords": [
                    "傅鹏博",
                    "赵枫",
                    "冯明远",
                    "基金经理",
                    "重仓股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "傅鹏博、赵枫、冯明远等顶流基金经理最新重仓股曝光",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康龙化成(300759)：H1收入持续提速 运营效率提升拉动业绩大幅增长",
            "features": {
                "keywords": [
                    "康龙化成",
                    "H1收入",
                    "运营效率",
                    "业绩增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康龙化成(300759)：H1收入持续提速 运营效率提升拉动业绩大幅增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【2359】药明康德6高层拟三个月内减持33万股A股|头条金融网 拟减持股份数量",
            "features": {
                "keywords": [
                    "药明康德",
                    "高层",
                    "减持",
                    "A股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【2359】药明康德6高层拟三个月内减持33万股A股|头条金融网 拟减持股份数量",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德(603259)：H1业绩超预期 临床研究及CDMO业务增长强劲",
            "features": {
                "keywords": [
                    "药明康德",
                    "H1业绩",
                    "临床研究",
                    "CDMO业务",
                    "增长强劲"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259)：H1业绩超预期 临床研究及CDMO业务增长强劲",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康臣药业（1681.HK）：与药明康德强强联合，奠定全方位肾科龙头地位",
            "features": {
                "keywords": [
                    "康臣药业",
                    "药明康德",
                    "肾科",
                    "龙头地位"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康臣药业（1681.HK）：与药明康德强强联合，奠定全方位肾科龙头地位",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "刘格菘仓位仍超90%、萧楠大幅增持银行股",
            "features": {
                "keywords": [
                    "刘格菘",
                    "萧楠",
                    "银行股",
                    "增持"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "刘格菘仓位仍超90%、萧楠大幅增持银行股",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "速递 | 开发下一代KRAS抑制剂，新锐完成近9000万美元B轮融资",
            "features": {
                "keywords": [
                    "KRAS抑制剂",
                    "新锐",
                    "融资"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "速递 | 开发下一代KRAS抑制剂，新锐完成近9000万美元B轮融资",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "速递 | 同时靶向TIGIT、PD-1和PVRIG三种免疫检查点，联合疗法完成首例给药",
            "features": {
                "keywords": [
                    "TIGIT",
                    "PD-1",
                    "PVRIG",
                    "免疫检查点",
                    "联合疗法",
                    "首例给药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "速递 | 同时靶向TIGIT、PD-1和PVRIG三种免疫检查点，联合疗法完成首例给药",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "重仓股“大换血”，二季报显露基金大咖“新宠”",
            "features": {
                "keywords": [
                    "重仓股",
                    "二季报",
                    "基金大咖",
                    "新宠"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "重仓股“大换血”，二季报显露基金大咖“新宠”",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]